Aktie A2DTBJ INNOVATION PHARMACEUTICALS INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Innovation Pharmaceuticals Inc.

Aktien

A2DTBJ

US45782D1000

IPIX

Markt geschlossen - OTC Markets
Andere Börsenplätze
 17:04:10 30.04.2024 		% 5 Tage % 1. Jan.
0.0015 USD -40.00% Intraday Chart für Innovation Pharmaceuticals Inc. -57.14% -69.39%
01.02. Innovation Pharmaceuticals Inc. kündigt Rücktritt von Vorstandsmitgliedern an CI
2023 Alfasigma S.p.A. und Innovation Pharmaceuticals Inc. kündigen exklusive Lizenzvereinbarung CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Innovation Pharmaceuticals Inc. Announces Resignation of Board Members
Alfasigma S.p.A. and Innovation Pharmaceuticals Inc. Terminate Exclusive License Agreement
Innovation Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended June 30, 2023
Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024
Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases
Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases
Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023
Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications
Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers
Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID Affiliated and Other Academic Researchers
Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission
INNOVATION PHARMACEUTICALS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
Innovation Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022
Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement
INNOVATION PHARMACEUTICALS INC. : Other Events (form 8-K)
Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin's Potential for Treating Fungal Keratitis
Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin’s Potential for Treating Fungal Keratitis
Innovation Pharmaceuticals Provides an Update on Ongoing Research on the Broad-Spectrum Antifungal Activity of Brilacidin
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2DTBJ Aktie
  4. Nachrichten Innovation Pharmaceuticals Inc.
  5. Andere Sprachen